clinical trial · NCT07619287
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
BeOne Medicines·phase1·recruiting·n = 118
Myeloid MalignancyBG-75202Hypomethylation Agent (HMA)
brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of BG-75202 (KAT6A/B inhibitor) alone and in combination with other agents in patients with myeloid malignancies.
started
Jun 23, 2026
primary completion
Sep 30, 2028
completion
Sep 30, 2028
last updated
Jun 30, 2026
official title
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BG-75202, Alone and in Combination With Other Agents, in Patients With Myeloid Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol